Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics

Aquestive Therapeutics, Inc. (AQST)

Today's Latest Price: $8.02 USD

0.46 (-5.42%)

Updated Sep 23 4:00pm

Add AQST to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 138 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

AQST Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AQST is -2.77 -- better than just 3.56% of US stocks.
  • AQST's went public 2.17 years ago, making it older than only 4.95% of listed US stocks we're tracking.
  • AQST's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.87% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aquestive Therapeutics Inc are PRTK, GEVO, CSTL, VIVE, and ADMS.
  • AQST's SEC filings can be seen here. And to visit Aquestive Therapeutics Inc's official web site, go to
AQST Daily Price Range
AQST 52-Week Price Range

AQST Stock Price Chart Technical Analysis Charts

AQST Price/Volume Stats

Current price $8.02 52-week high $10.00
Prev. close $8.48 52-week low $1.41
Day low $7.85 Volume 983,812
Day high $8.60 Avg. volume 891,317
50-day MA $6.96 Dividend yield N/A
200-day MA $5.05 Market Cap 269.63M

Aquestive Therapeutics, Inc. (AQST) Company Bio

Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.

AQST Latest News Stream

Event/Time News Detail
Loading, please wait...

AQST Latest Social Stream

Loading social stream, please wait...

View Full AQST Social Stream

Latest AQST News From Around the Web

Below are the latest news stories about Aquestive Therapeutics Inc that investors may wish to consider to help them evaluate AQST as an investment opportunity.

Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial -

DUBLIN--(BUSINESS WIRE) published a new article on the allergy drugs industry "Allergy Drugs" Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from

Business Wire | September 11, 2020

Aquestive launches early-stage study of sublingual epinephrine for allergic reactions

Aquestive Therapeutics (AQST) initiates a Phase 1 clinical trial in 28 healthy volunteers evaluating the safety and pharmacokinetics ((PK)) of AQST-108, an oral sublingual formulation of epinephrine, for the potential treatment of allergic reactions, including anaphylaxis (acute allergic reactions).The crossover design study will compare the PK and pharmacodynamics of AQST-108 with...

Seeking Alpha | August 20, 2020

Are Insiders Buying Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock?

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

Yahoo | August 20, 2020

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

* First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis * Pharmacokinetic and pharmacodynamics data expected in fourth quarter 2020WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the initiation of a Phase 1 Pharmacokinetic (PK) trial for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® techn...

Yahoo | August 20, 2020

Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher

Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Yahoo | August 18, 2020

Read More 'AQST' Stories Here

AQST Price Returns

1-mo 1.65%
3-mo 50.19%
6-mo 250.22%
1-year 157.88%
3-year N/A
5-year N/A
YTD 37.80%
2019 -7.62%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching AQST

Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:

Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1817 seconds.